| 摘要 |
Compounds of formula (1) are inhibitors of HSP90 activity in vitro or in vivo, and of use in the treatment of inter alia, cancer wherein R<SUB>2 </SUB>is a group of formula -(Ar<SUP>1</SUP>)<SUB>m</SUB>-(Alk<SUP>1</SUP>)<SUB>P</SUB>-(Z)<SUB>r</SUB>-(Alk<SUP>2</SUP>)<SUB>S</SUB>-Q wherein Ar<SUP>1 </SUP>is an optionally substituted aryl or heteroaryl radical, Alk' and Alk 2 are optionally substituted divalent C<SUB>1</SUB>-C<SUB>3 </SUB>alkylene or C<SUB>2</SUB>-C<SUB>3 </SUB>alkenylene radicals, m, p, r and s are independently 0 or 1, Z is -0-, -S-, -(C-O)-, -(C-S)-, -S0<SUB>2</SUB>-, -C(-O)O-, -C(-O)NR<SUP>A</SUP>-, -C(-S)NR<SUP>A</SUP>-, -S0<SUB>2</SUB>NR<SUP>A</SUP>-, -NR<SUP>A</SUP>C(-O)_, -NR<SUP>A</SUP>S0<SUB>2</SUB>- or -NR<SUP>A</SUP>-wherein R<SUP>A </SUP>is hydrogen or C<SUB>1</SUB>-C<SUB>6 </SUB>alkyl, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; R<SUB>3 </SUB>is hydrogen, an optional substituent, or an optionally substituted (C<SUB>1</SUB>-C<SUB>6</SUB>)alkyl, aryl or heteroaryl radical; and R<SUB>4 </SUB>is a carboxylic ester, carboxamide or sulfonamide group.
|
